PLoS ONE (Jan 2019)

Immunosuppressive regimens based on Cyclophospamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy.

  • Maria Stangou,
  • Smaragdi Marinaki,
  • Evangelos Papachristou,
  • Kyriaki Kolovou,
  • Erasmia Sambani,
  • Synodi Zerbala,
  • Panagiota Papadea,
  • Olga Balafa,
  • Karolos-Pavlos Rapsomanikis,
  • Aimilios Andrikos,
  • Panagiota Manolakaki,
  • Dorothea Papadopoulou,
  • Efstathios Mitsopoulos,
  • Helen Liakou,
  • Paraskevi-Evi Andronikidi,
  • Vasiliki Choulitoudi,
  • George Moustakas,
  • Dimitra Galitsiou,
  • Eugene Dafnis,
  • Kostas Stylianou,
  • Ioannis Stefanidis,
  • Spyridon Golfinopoulos,
  • Stylianos Panagoutsos,
  • Maria Tsilivigkou,
  • Apostolos Papadogianakis,
  • Ioannis Tzanakis,
  • Athanasios Sioulis,
  • Dimitrios Vlachakos,
  • Eirini Grapsa,
  • Sophia Spaia,
  • Nikolaos Kaperonis,
  • Christos Paliouras,
  • Christos Dioudis,
  • Fani Papoulidou,
  • Theofanis Apostolou,
  • Christos Iatrou,
  • Ioannis Boletis,
  • Dimitrios Goumenos,
  • Aikaperini Papagianni

DOI
https://doi.org/10.1371/journal.pone.0217116
Journal volume & issue
Vol. 14, no. 8
p. e0217116

Abstract

Read online

IntroductionManagement of the Primary Membranous Nephropathy (PMN) usually involves administration of immunosuppressives. Cyclophosphamide (Cyclo) and Calcineurin Inhibitors (CNIs) are both widely used but only limited data exist to compare their efficacy in long term follow-up.AimThe aim of the present study was to estimate and compare long term effects of Cyclo and CNIs in patients with PMN.Patients-methodsClinical data, histologic findings and long term outcome were retrospectively studied. The response to treatment and rate of relapse was compared between patients treated with CNIs or Cyclo based immunosuppressive regimens.ResultsTwenty three centers participated in the study, with 752 PMN patients (Mean age 53.4(14-87) yrs, M/F 467/285), followed for 10.1±5.7 years. All patients were initially treated with Renin Angiotensin Aldosterone System inhibitors (RAASi) for at least 6 months. Based on their response and tolerance to initial treatment, patients were divided into 3 groups, group I with spontaneous remission, who had no further treatment, group II, continued on RAASi only, and group III on RAASi+immunosuppression. Immunosuppressive regimes were mainly based on CNIs or Cyclo. Frequent relapses and failure to treatment were more common between patients who had started on CNIs (n = 381) compared to those initially treated with Cyclo (n = 110), relapse rate: 25.2% vs. 6.4%, pConclusionsLong term follow up showed that administration of Cyclo in PMN is followed by better preservation of renal function, increased response rate and less frequent relapses, compared to CNIs.